PD-1/ PD-L1 bispecific antibody IBI318 combined with lenvatinib in advanced non-small cell lung cancer with acquired resistance to immune checkpoint inhibitors: a phase II trial

Journal:

Nature Communications

Published:

2025-12-15

DOI:

10.1038/s41467-025-67262-x

Affiliations:

19

Authors:

36

Go to article

Institutions	Authors	Share
Hunan Cancer Hospital, China	14.500000 14.500000	0.40
Central South University (CSU), China	13.916667 13.916667	0.39
West China School of Medicine/West China Hospital of Sichuan University (WCSM/WCH), SCU, China	2.000000	0.06
Yiyang Central Hospital, China	1.000000	0.03
Qinghai Provincial People's Hospital, China	1.000000	0.03
The University of Hong Kong (HKU), China	1.000000	0.03
Innovent Biologics, Inc., China	1.000000	0.03
Xiangya School of Medicine, CSU, China	0.666667	0.02
The Third Xiangya Hospital, CSU, China	0.333333	0.01
Qinghai University, China	0.333333	0.01
Hengyang Medical School, USC, China	0.250000	0.01

Interested in Oncology and Carcinogenesis?